Literature DB >> 8726155

Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia.

T F Fok1, S Monkman, M Dolovich, S Gray, G Coates, B Paes, F Rashid, M Newhouse, H Kirpalani.   

Abstract

The best means for optimal delivery of drugs into lungs of infants with bronchopulmonary dysplasia (BPD) is uncertain. We aimed to measure radio-aerosol deposition of salbutamol by jet nebulizer and metered dose inhalers (MDI) in ventilated and non-ventilated BPD infants. In a randomized, crossover sequence, salbutamol lung deposition was measured using an MDI (2 puffs or 200 micrograms) or sidestream jet nebulizer (5 minutes of nebulization with 100 micrograms/kg) in 10 ventilated (mean birthweight, 1,101 g) and 13 non-ventilated (mean birthweight, 1,093 g) prematurely born infants. Non-ventilated infants inhaled aerosol through a face mask, connected to a nebulizer or an MDI and spacer (Aerochamber). Ventilated infants received aerosol from an MDI + MV15 Aerochamber or a nebulizer inserted in the ventilator circuit. Lung deposition by both methods was low: mean (SEM) from the MDI was 0.67 (0.17)% of the actuated dose, and from the nebulizer it was 1.74 (0.21)% and 0.28 (0.04)% of the nebulized and initial reservoir doses, respectively. Corresponding figures for the ventilated infants were 0.98 (0.19)% from the MDI and 0.95 (0.23)% and 0.22 (0.08)% from the nebulizer. In both groups, and for both methods of delivery, there was marked inter-subject variability in lung deposition and a tendency for the aerosol to be distributed to the central lung regions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726155     DOI: 10.1002/(SICI)1099-0496(199605)21:5<301::AID-PPUL5>3.0.CO;2-P

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  41 in total

Review 1.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 2.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

4.  Generating Charged Pharmaceutical Aerosols Intended to Improve Targeted Drug Delivery in Ventilated Infants.

Authors:  Landon Holbrook; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2015-10-01       Impact factor: 3.433

5.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 6.  Aerosol delivery to ventilated newborn infants: historical challenges and new directions.

Authors:  Jan Mazela; Richard A Polin
Journal:  Eur J Pediatr       Date:  2010-09-28       Impact factor: 3.183

Review 7.  Measurements of deposited aerosol dose in infants and small children.

Authors:  Timothy E Corcoran
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Treatment of childhood asthma. Options and rationale for inhaled therapy.

Authors:  C V Powell; M L Everard
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

9.  Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease.

Authors:  T F Fok; K Lam; P C Ng; H K So; K L Cheung; W Wong; K W So
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-09       Impact factor: 5.747

Review 10.  Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.

Authors:  Geraldine Ng; Orlando da Silva; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.